- Home
- SYM vs IMVT Comparison
SYM vs IMVT Comparison
Compare SYM & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYM
- IMVT
- Stock Information
- Founded
- SYM 2005
- IMVT 2018
- Country
- SYM United States
- IMVT United States
- Employees
- SYM N/A
- IMVT N/A
- Industry
- SYM Industrial Machinery/Components
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SYM Industrials
- IMVT Health Care
- Exchange
- SYM Nasdaq
- IMVT Nasdaq
- Market Cap
- SYM 3.2B
- IMVT 2.7B
- IPO Year
- SYM N/A
- IMVT N/A
- Fundamental
- Price
- SYM $53.95
- IMVT $16.08
- Analyst Decision
- SYM Buy
- IMVT Buy
- Analyst Count
- SYM 13
- IMVT 11
- Target Price
- SYM $37.73
- IMVT $37.38
- AVG Volume (30 Days)
- SYM 2.6M
- IMVT 1.3M
- Earning Date
- SYM 08-06-2025
- IMVT 08-08-2025
- Dividend Yield
- SYM N/A
- IMVT N/A
- EPS Growth
- SYM N/A
- IMVT N/A
- EPS
- SYM N/A
- IMVT N/A
- Revenue
- SYM $2,071,248,000.00
- IMVT N/A
- Revenue This Year
- SYM $24.54
- IMVT N/A
- Revenue Next Year
- SYM $31.39
- IMVT N/A
- P/E Ratio
- SYM N/A
- IMVT N/A
- Revenue Growth
- SYM 42.16
- IMVT N/A
- 52 Week Low
- SYM $16.32
- IMVT $12.72
- 52 Week High
- SYM $55.75
- IMVT $34.47
- Technical
- Relative Strength Index (RSI)
- SYM 66.15
- IMVT 41.15
- Support Level
- SYM $50.26
- IMVT $15.31
- Resistance Level
- SYM $54.57
- IMVT $17.12
- Average True Range (ATR)
- SYM 3.25
- IMVT 0.84
- MACD
- SYM -0.48
- IMVT -0.27
- Stochastic Oscillator
- SYM 85.04
- IMVT 20.53
About SYM Symbotic Inc.
Symbotic Inc is an automation technology company that develops technologies to improve operating efficiencies in modern warehouses. The group develops, commercializes, and deploys end-to-end technology solutions that dramatically improve supply chain operations. Th company also automates the processing of pallets and cases in large warehouses or distribution centers for some of the retail and wholesale companies in the world. The company operates in two geographical regions the United States and Canada. Key revenue is generated from the United States.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.